NanoViricides is expected to report zero revenue and a consensus loss of $0.10 per share on November 13, 2026, with the stock currently trading at $1.44 against a bullish average analyst price target of $6.00.
Investors are primarily focused on the company's cash runway and clinical progress for its lead drug candidate, NV-387, which is currently in Phase II trials for Mpox and Ebola.
Recently, the company announced the advancement of a Measles drug program to address U.S. outbreaks, adding a significant new potential milestone to its pipeline. However, following a "going concern" disclosure in its fiscal 10-K, evidence of successful capital management and trial recruitment remains critical for maintaining investor confidence.